Stephen Hoge - Feb 28, 2025 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: President
Signature: /s/ James Dillon, as Attorney-in-Fact
Stock symbol: MRNA
Transactions as of: Feb 28, 2025
Transactions value $: -$19,027
Form type: 4
Date filed: 3/3/2025, 04:41 PM
Previous filing: Feb 28, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Options Exercise		+652	+0.04%		1.45M	Feb 28, 2025	Direct	F1
transaction	MRNA	Common Stock	Tax liability	-$9.82K	-316	-0.02%	$31.09	1.45M	Feb 28, 2025	Direct	F2
transaction	MRNA	Common Stock	Options Exercise		+611	+0.04%		1.45M	Feb 28, 2025	Direct	F1
transaction	MRNA	Common Stock	Tax liability	-$9.2K	-296	-0.02%	$31.09	1.45M	Feb 28, 2025	Direct	F2
holding	MRNA	Common Stock						4.12K	Feb 28, 2025	By Valhalla, LLC
holding	MRNA	Common Stock						152K	Feb 28, 2025	By Trust	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Restricted Stock Units	Options Exercise	$0	-652	-20.01%	$0.00	2.61K	Feb 28, 2025	Common Stock	652		Direct	F1, F4
transaction	MRNA	Restricted Stock Units	Options Exercise	$0	-611	-11.12%	$0.00	4.88K	Feb 28, 2025	Common Stock	611		Direct	F1, F5
transaction	MRNA	Stock Option (Right to Buy)	Award	$0	+238K		$0.00	238K	Mar 1, 2025	Common Stock	238K	$30.96	Direct	F6
transaction	MRNA	Restricted Stock Units	Award	$0	+149K		$0.00	149K	Mar 1, 2025	Common Stock	149K		Direct	F1, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F3	These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F4	25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F5	25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F6	25% of this option will vest and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F7	25% of the shares subject to this restricted stock unit award will vest on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.